ArticleFrontiers in nutrition2025
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Modulation of the gut microbiota by traditional Chinese medicine to attenuate chemotherapy-induced toxicity in gastric cancer: a review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Traditional Chinese medicine-based modulation of gut microbiota in coronary heart disease: probiotic synergy and translational perspectives.Frontiers in cardiovascular medicine · 2026Review
- Dietary Bazhen San solid-state fermentation product improves laying performance, immunity and intestinal health in laying hens during the late laying period.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study investigated the effects of a compound preparation combining Materials and methods: A CRF model was established in C57BL/6NCr mice using 5-fluorouracil. Mice were divided into four groups receiving varying concentrations of LB-Pro. Over 14 days, interventions were administered, followed by treadmill exhaustion tests to assess fatigue levels. Body weight, serum biomarkers (TNF- Results: Administration of medium- and high-concentration LB-Pro significantly improved fatigue-related outcomes, including prolonged exhaustion times and enhanced antioxidant enzyme activities, compared to the control group. Low-concentration LB-Pro showed limited efficacy. Gut microbiota analysis revealed alterations in microbial composition, including enrichment of short-chain fatty acid-producing taxa, and metabolic pathways associated with energy metabolism and antioxidant defense were upregulated in probiotic-treated groups. Conclusion: LB-Pro alleviated chemotherapy-induced CRF in mice, likely through modulation of gut microbiota and enhancement of mitochondrial energy metabolism and antioxidant systems. These findings highlight the potential of integrative approaches combining traditional Chinese medicine and probiotics for managing CRF, emphasizing the gut microbiota-metabolic axis as a key therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.